Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity: a pilot study

Marcos M. Lima-Martínez, Mariela Paoli, Marianela Rodney, Nathalie Balladares, Miguel Contreras, Luis D’Marco, Gianluca Iacobellis

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The aim of the study was to assess the effect of sitagliptin addition on the epicardial adipose tissue (EAT) thickness in subjects with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. This was a 24-week interventional pilot study in 26 consecutive type 2 diabetic patients, 14 females and 12 males average age of 43.8 ± 9.0 years, with Hemoglobin A1c (HbA1c) ≥7 % on metformin monotherapy. Subjects who met the inclusion criteria were added on sitagliptin and started on sitagliptin/metformin combination at the dosage of 50 mg/1000 mg twice daily. EAT and visceral and total body fat were measured, respectively, with echocardiography and bioelectrical impedance analysis at baseline and after 24 weeks of sitagliptin/metformin treatment in each subject. HbA1c and plasma lipids were also measured. EAT decreased significantly from 9.98 ± 2.63 to 8.10 ± 2.11 mm, p = 0.001, accounting for a percentage of reduction (∆ %) of −15 % after 24 weeks of sitagliptin addition, whereas total body fat percentage, visceral fat, and body mass index (BMI), decreased by 8, 12, and 7 %, respectively (p = 0.001 for all). After 6 month, EAT ∆ % was significantly correlated with ∆ % of visceral fat (r = 0.456; p = 0.01), whereas no correlation with either BMI ∆ % (r = 0.292; p = 0.147) or HbA1c ∆ % was found. The addition of Sitagliptin produced a significant and rapid reduction of EAT, marker of organ-specific visceral fat, in overweight/obese individuals with type 2 diabetes inadequately controlled on metformin monotherapy. EAT as measured with ultrasound can serve as no invasive and accurate marker of visceral fat changes during pharmaceutical interventions targeting the fat.

Original languageEnglish (US)
Pages (from-to)448-455
Number of pages8
JournalEndocrine
Volume51
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

Type 2 Diabetes Mellitus
Adipose Tissue
Intra-Abdominal Fat
Metformin
Obesity
Fats
Hemoglobins
Body Mass Index
Fat Body
Sitagliptin Phosphate
Electric Impedance
Echocardiography
Lipids
Pharmaceutical Preparations

Keywords

  • Diet
  • Epicardial adipose tissue
  • Epicardial fat
  • Exercise
  • Sitagliptin

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Lima-Martínez, M. M., Paoli, M., Rodney, M., Balladares, N., Contreras, M., D’Marco, L., & Iacobellis, G. (2016). Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity: a pilot study. Endocrine, 51(3), 448-455. https://doi.org/10.1007/s12020-015-0710-y

Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity : a pilot study. / Lima-Martínez, Marcos M.; Paoli, Mariela; Rodney, Marianela; Balladares, Nathalie; Contreras, Miguel; D’Marco, Luis; Iacobellis, Gianluca.

In: Endocrine, Vol. 51, No. 3, 01.03.2016, p. 448-455.

Research output: Contribution to journalArticle

Lima-Martínez, MM, Paoli, M, Rodney, M, Balladares, N, Contreras, M, D’Marco, L & Iacobellis, G 2016, 'Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity: a pilot study', Endocrine, vol. 51, no. 3, pp. 448-455. https://doi.org/10.1007/s12020-015-0710-y
Lima-Martínez MM, Paoli M, Rodney M, Balladares N, Contreras M, D’Marco L et al. Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity: a pilot study. Endocrine. 2016 Mar 1;51(3):448-455. https://doi.org/10.1007/s12020-015-0710-y
Lima-Martínez, Marcos M. ; Paoli, Mariela ; Rodney, Marianela ; Balladares, Nathalie ; Contreras, Miguel ; D’Marco, Luis ; Iacobellis, Gianluca. / Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity : a pilot study. In: Endocrine. 2016 ; Vol. 51, No. 3. pp. 448-455.
@article{5530ebf9fab34119b4dd8535e27e1d85,
title = "Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity: a pilot study",
abstract = "The aim of the study was to assess the effect of sitagliptin addition on the epicardial adipose tissue (EAT) thickness in subjects with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. This was a 24-week interventional pilot study in 26 consecutive type 2 diabetic patients, 14 females and 12 males average age of 43.8 ± 9.0 years, with Hemoglobin A1c (HbA1c) ≥7 {\%} on metformin monotherapy. Subjects who met the inclusion criteria were added on sitagliptin and started on sitagliptin/metformin combination at the dosage of 50 mg/1000 mg twice daily. EAT and visceral and total body fat were measured, respectively, with echocardiography and bioelectrical impedance analysis at baseline and after 24 weeks of sitagliptin/metformin treatment in each subject. HbA1c and plasma lipids were also measured. EAT decreased significantly from 9.98 ± 2.63 to 8.10 ± 2.11 mm, p = 0.001, accounting for a percentage of reduction (∆ {\%}) of −15 {\%} after 24 weeks of sitagliptin addition, whereas total body fat percentage, visceral fat, and body mass index (BMI), decreased by 8, 12, and 7 {\%}, respectively (p = 0.001 for all). After 6 month, EAT ∆ {\%} was significantly correlated with ∆ {\%} of visceral fat (r = 0.456; p = 0.01), whereas no correlation with either BMI ∆ {\%} (r = 0.292; p = 0.147) or HbA1c ∆ {\%} was found. The addition of Sitagliptin produced a significant and rapid reduction of EAT, marker of organ-specific visceral fat, in overweight/obese individuals with type 2 diabetes inadequately controlled on metformin monotherapy. EAT as measured with ultrasound can serve as no invasive and accurate marker of visceral fat changes during pharmaceutical interventions targeting the fat.",
keywords = "Diet, Epicardial adipose tissue, Epicardial fat, Exercise, Sitagliptin",
author = "Lima-Mart{\'i}nez, {Marcos M.} and Mariela Paoli and Marianela Rodney and Nathalie Balladares and Miguel Contreras and Luis D’Marco and Gianluca Iacobellis",
year = "2016",
month = "3",
day = "1",
doi = "10.1007/s12020-015-0710-y",
language = "English (US)",
volume = "51",
pages = "448--455",
journal = "Endocrine",
issn = "1355-008X",
publisher = "Humana Press",
number = "3",

}

TY - JOUR

T1 - Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity

T2 - a pilot study

AU - Lima-Martínez, Marcos M.

AU - Paoli, Mariela

AU - Rodney, Marianela

AU - Balladares, Nathalie

AU - Contreras, Miguel

AU - D’Marco, Luis

AU - Iacobellis, Gianluca

PY - 2016/3/1

Y1 - 2016/3/1

N2 - The aim of the study was to assess the effect of sitagliptin addition on the epicardial adipose tissue (EAT) thickness in subjects with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. This was a 24-week interventional pilot study in 26 consecutive type 2 diabetic patients, 14 females and 12 males average age of 43.8 ± 9.0 years, with Hemoglobin A1c (HbA1c) ≥7 % on metformin monotherapy. Subjects who met the inclusion criteria were added on sitagliptin and started on sitagliptin/metformin combination at the dosage of 50 mg/1000 mg twice daily. EAT and visceral and total body fat were measured, respectively, with echocardiography and bioelectrical impedance analysis at baseline and after 24 weeks of sitagliptin/metformin treatment in each subject. HbA1c and plasma lipids were also measured. EAT decreased significantly from 9.98 ± 2.63 to 8.10 ± 2.11 mm, p = 0.001, accounting for a percentage of reduction (∆ %) of −15 % after 24 weeks of sitagliptin addition, whereas total body fat percentage, visceral fat, and body mass index (BMI), decreased by 8, 12, and 7 %, respectively (p = 0.001 for all). After 6 month, EAT ∆ % was significantly correlated with ∆ % of visceral fat (r = 0.456; p = 0.01), whereas no correlation with either BMI ∆ % (r = 0.292; p = 0.147) or HbA1c ∆ % was found. The addition of Sitagliptin produced a significant and rapid reduction of EAT, marker of organ-specific visceral fat, in overweight/obese individuals with type 2 diabetes inadequately controlled on metformin monotherapy. EAT as measured with ultrasound can serve as no invasive and accurate marker of visceral fat changes during pharmaceutical interventions targeting the fat.

AB - The aim of the study was to assess the effect of sitagliptin addition on the epicardial adipose tissue (EAT) thickness in subjects with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. This was a 24-week interventional pilot study in 26 consecutive type 2 diabetic patients, 14 females and 12 males average age of 43.8 ± 9.0 years, with Hemoglobin A1c (HbA1c) ≥7 % on metformin monotherapy. Subjects who met the inclusion criteria were added on sitagliptin and started on sitagliptin/metformin combination at the dosage of 50 mg/1000 mg twice daily. EAT and visceral and total body fat were measured, respectively, with echocardiography and bioelectrical impedance analysis at baseline and after 24 weeks of sitagliptin/metformin treatment in each subject. HbA1c and plasma lipids were also measured. EAT decreased significantly from 9.98 ± 2.63 to 8.10 ± 2.11 mm, p = 0.001, accounting for a percentage of reduction (∆ %) of −15 % after 24 weeks of sitagliptin addition, whereas total body fat percentage, visceral fat, and body mass index (BMI), decreased by 8, 12, and 7 %, respectively (p = 0.001 for all). After 6 month, EAT ∆ % was significantly correlated with ∆ % of visceral fat (r = 0.456; p = 0.01), whereas no correlation with either BMI ∆ % (r = 0.292; p = 0.147) or HbA1c ∆ % was found. The addition of Sitagliptin produced a significant and rapid reduction of EAT, marker of organ-specific visceral fat, in overweight/obese individuals with type 2 diabetes inadequately controlled on metformin monotherapy. EAT as measured with ultrasound can serve as no invasive and accurate marker of visceral fat changes during pharmaceutical interventions targeting the fat.

KW - Diet

KW - Epicardial adipose tissue

KW - Epicardial fat

KW - Exercise

KW - Sitagliptin

UR - http://www.scopus.com/inward/record.url?scp=84959530863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959530863&partnerID=8YFLogxK

U2 - 10.1007/s12020-015-0710-y

DO - 10.1007/s12020-015-0710-y

M3 - Article

C2 - 26233684

AN - SCOPUS:84959530863

VL - 51

SP - 448

EP - 455

JO - Endocrine

JF - Endocrine

SN - 1355-008X

IS - 3

ER -